Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

Prior treatment

• Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment.

Other illness

• Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.
• Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.
• Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.
• Patients with severe heart and lung dysfunction.
• Patients with severe chronic diseases of kidney, liver and other important organs.
• Patients with any other serious illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on.
• Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.

Other

• Patients with two or more kinds of tumors.
• Patients who need long-term use of glucocorticoid.
• Women patients in gestation period or suckling period.

• Pathologically diagnosed IIIB or IV non-small cell lung cancer.
• Previously accepted first-line standard treatment failure or recurrence
• At least one measurable lesion.
• The patient has not received any other anti-cancer treatment within four weeks.
• Any gender, age ≥18 years
• ECOG PS : 0-2 points
• Expected survival ≥ 6 months
• The level of organ function meets the following criteria.
  • (1) subject to the standard blood test: ANC ≥ 1.5×109 / L, PLT ≥ 50×109 / L, Hb ≥ 90g/L.
  • (2) biochemical tests must meet the following criteria: TBIL\<1.5×ULN, ALT, AST \<2.5×ULN ( if liver metastasis ALT, AST can be \<5×ULN), BUN, and Cr ≤ 1×ULN).
  • 9\. Female patients in child bearing period must have evidence of negative pregnancy test, and agree to take effective contraceptive measures until 6months after therapy.
  • 10\. Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.